Rebecca Robbins

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access to weight-loss drugs paid for Medicare and Medicaid.

In a new nonfiction book, the Y.A. novelist describes the disease as a window into “the folly and brilliance and cruelty and compassion of humans.”

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are now.

Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare and Medicaid are not eligible.

Medicare to Negotiate Lower Prices for Weight-Loss Drugs

Attempts to restrict pharmaceutical advertisements have failed many times over the years, often on First Amendment grounds.

Robert F. Kennedy Jr. and other candidates for top health posts are at odds with the drug industry, setting the stage for tense battles over regulatory changes.

GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.

Both have campaigned for lower prescription costs. Kamala Harris has promised to expand President Biden’s policies. Donald Trump is a wild card.

The Biden administration said it would have saved $6 billion had the new prices been in effect last year.